Antibodies to mutated citrullinated vimentin and anti-cyclic citrullinated peptide antibodies in inflammatory bowel disease and related arthritis

被引:7
|
作者
Al-Jarallah, Khaled [1 ]
Shehab, Diaa [1 ]
Al-Attiyah, Rajaa [2 ]
Al-Azmi, Waleed [1 ]
Al-Fadli, Ahmad [3 ]
Haider, Mohammed Zafar [4 ]
Panaccione, Remo [5 ]
Ghosh, Subrata [5 ]
机构
[1] Kuwait Univ, Dept Med, Fac Med, Safat 13110, Kuwait
[2] Kuwait Univ, Dept Microbiol, Fac Med, Safat 13110, Kuwait
[3] Mubarak Al Kabeer Hosp, Dept Gastroenterol, Safat, Kuwait
[4] Kuwait Univ, Dept Pediat, Fac Med, Safat 13110, Kuwait
[5] Univ Calgary, Div Med, Fac Med, Calgary, AB T2N 1N4, Canada
关键词
arthritis; anti-cyclic citrullinated peptide antibodies; anti-mutated citrullinated vimentin; inflammatory bowel disease; spondylarthropathies; MUSCULOSKELETAL MANIFESTATIONS; RHEUMATOID-ARTHRITIS; CLASSIFICATION; EPIDEMIOLOGY; PREVALENCE; CCP;
D O I
10.1002/ibd.21937
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Antibodies that react with citrullinated proteins (anti-mutated citrullinated vimentin [anti-MCV] and second-generation anti-cyclic citrullinated peptide antibodies [anti-CCP2]) are markers for rheumatoid arthritis. Recent studies have demonstrated that these antibodies are present in other arthropathies including the spondyloarthritis, psoriatic arthritis, and juvenile idiopathic arthritis. Arthritis associated with inflammatory bowel disease (IBD) takes various forms, with some shared similarities with classic spondylarthropathies. Our objective was to investigate the role of anti-MCV and anti-CCP2 as potential biomarkers in IBD and related arthritis. Methods: In all, 125 IBD patients (71 males, 54 females) were compared to 81 age- and sex-matched healthy controls. Anti-MCV and Anti-CCP2 IgG were measured using an enzyme linked immunosorbent assay. Results: In the 125 IBD patients (mean age 32.6 +/- 12.3 years), 44 (35.2%) had ulcerative colitis and 81 (64.8%) had Crohn's disease. Forty-four (35.2%) IBD patients developed arthritic manifestations. Antibody positivity was observed in 24/125 (19.2%) IBD patients and in 18/81 (22.2%) healthy subjects. The proportion of anti-MCV positivity among IBD patients and healthy individuals were similar: 16.8% vs. 16.0%, P = 0.887. Anti-CCP2 positivity among IBD patients and healthy individuals was also comparable: 6.4% vs. 6.2%, P = 0.948. Similarly, the presence of anti-MCV and anti-CCP2 antibodies was not different among IBD patients with and without arthritis. The mean titers of antibodies were low: anti-MCV (29.6 +/- 7.5 U/mL) and anti-CCP2 (27.6 +/- 4.0 U/mL) in IBD patients with arthritis. Conclusions: Autoantibodies to citrullinated proteins were low in IBD-related arthritis. These findings suggest that these antibodies are not useful biomarkers in IBD to predict who may develop IBD-related arthropathy. (Inflamm Bowel Dis 2012)
引用
收藏
页码:1655 / 1662
页数:8
相关论文
共 50 条
  • [1] Anti-Cyclic Citrullinated Peptide Antibodies and Inflammatory Bowel Disease
    Mukherjee, Jaita
    Mouyis, Maria
    Shah, Kavina
    Saeidinejad, Mohammad Mahdi
    Akbar, Ayesha
    Hamdulay, Shahir
    [J]. ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [2] THE DIAGNOSTIC UTILITY OF ANTI-MUTATED CITRULLINATED VIMENTIN ANTIBODIES, ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODIES AND RHEUMATOID FACTOR IN RHEUMATOID ARTHRITIS
    Eldin, A. Radr
    Mobasher, S. A.
    Hegazy, G.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 898 - 898
  • [3] Evaluation of Anti-Mutated Citrullinated Vimentin Antibodies, Anti-Cyclic Citrullinated Peptide Antibodies and Rheumatoid Factor in Omani Patients with Rheumatoid Arthritis
    Al-Shukaili, Ahmed
    Al-Ghafri, Saif
    Al-Marhoobi, Safia
    Alkaabi, Juma
    [J]. INTERNATIONAL JOURNAL OF RHEUMATOLOGY, 2012, 2012
  • [4] Diagnostic utility of anti-cyclic citrullinated peptide and anti-modified citrullinated vimentin antibodies in rheumatoid arthritis
    Keskin, Goksal
    Inal, Ali
    Keskin, Dilek
    Pekel, Aysel
    Baysal, Ozan
    Dizer, Ufuk
    Sengul, Ali
    [J]. PROTEIN AND PEPTIDE LETTERS, 2008, 15 (03): : 314 - 317
  • [5] Anti-mutated Citrullinated Vimentin Antibodies (Anti-mcv) and Anti-cyclic Citrullinated Peptide Antibodies (ANTI-CCP): Association with Disease Activity Measures in Rheumatoid Arthritis
    Ponce-Guarneros, J. M.
    Diaz-Toscano, M. L.
    Rocha-Munoz, A. D.
    Zavaleta-Muniz, S. A.
    Gonzalez-Montoya, N.
    Corona-Sanchez, E. G.
    Felix-Hernandez, F.
    Totsuka-Sutto, S.
    Garcia-Cobian, T.
    Salazar-Paramo, M.
    Cardona-Munoz, E. G.
    Fuentes-Gonzalez, C.
    Loaiza-Cardenas, C. A.
    Gamez-Nava, J., I
    Gonzalez-Lopez, L.
    [J]. JOURNAL OF RHEUMATOLOGY, 2011, 38 (06) : 1202 - 1202
  • [6] Antibodies to mutated citrullinated vimentin and antibodies to cyclic citrullinated peptides in juvenile idiopathic arthritis
    Kuna, Andrea Tesija
    Lamot, Lovro
    Miler, Marijana
    Harjacek, Miroslav
    Simundic, Ana-Maria
    Vrkic, Nada
    [J]. CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2009, 47 (12) : 1525 - 1530
  • [7] Anti-cyclic citrullinated peptide antibodies in advanced rheumatoid arthritis
    Pinheiro, GC
    Scheinberg, MA
    da Silva, MA
    Maciel, S
    [J]. ANNALS OF INTERNAL MEDICINE, 2003, 139 (03) : 234 - 235
  • [8] Are anti-cyclic citrullinated peptide antibodies pathogenic in rheumatoid arthritis?
    Holers, V. Michael
    [J]. NATURE CLINICAL PRACTICE RHEUMATOLOGY, 2006, 2 (08): : 400 - 401
  • [9] Anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis
    R. Gupta
    M. M. Thabah
    B. Vaidya
    S. Gupta
    R. Lodha
    S. K. Kabra
    [J]. The Indian Journal of Pediatrics, 2010, 77 : 41 - 44
  • [10] Anti-cyclic Citrullinated Peptide Antibodies in Juvenile Idiopathic Arthritis
    Gupta, R.
    Thabah, M. M.
    Vaidya, B.
    Gupta, S.
    Lodha, R.
    Kabra, S. K.
    [J]. INDIAN JOURNAL OF PEDIATRICS, 2010, 77 (01): : 41 - 44